In urothelial carcinoma (n = 20, 2–6 tumors per patient), HER2 expression was more frequent, with ≥2+ expression observed in six (30%) cases and 3+ expression observed in three (15%) cases in at least one tumor. Here, ERBB2 is linked to urothelial carcinoma.